{
    "xml": "<topic id=\"PHP2234\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/levomepromazine\" basename=\"levomepromazine\" title=\"LEVOMEPROMAZINE\">\n<title>LEVOMEPROMAZINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_375\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/levomepromazine\">Levomepromazine</xref>\n</p>\n<data name=\"vtmid\">89029005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n<p outputclass=\"synonyms\">Methotrimeprazine</p>\r\n</body>\n<topic id=\"PHP47442\" outputclass=\"indicationsAndDose\" rev=\"1.28\" parent=\"/drugs/levomepromazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pain in palliative care (reserved for distressed patients with severe pain unresponsive to other measures)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous subcutaneous infusion or by intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Seek specialist advice.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Restlessness and confusion in palliative care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 years</p>\n<p>0.35&#8211;3&#8239;mg/kg, to be administered over 24 hours.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>12.5&#8211;200&#8239;mg, to be administered over 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>6&#8239;mg every 2&#8239;hours as required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>6.25&#8239;mg every 2&#8239;hours as required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 12.5&#8211;50&#8239;mg/24 hours, titrated according to response (doses greater than 100&#8239;mg/24 hours should be given under specialist supervision).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting in palliative care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous intravenous infusion or by subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years</p>\n<p>100&#8211;400&#8239;micrograms/kg, to be administered over 24 hours.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>5&#8211;25&#8239;mg, to be administered over 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>6&#8239;mg once daily, dose to be taken at bedtime, increased if necessary to 12.5&#8211;25&#8239;mg twice daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>6.25&#8239;mg once daily, dose to be given at bedtime, increased if necessary to 12.5&#8211;25&#8239;mg twice daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8211;25&#8239;mg/24 hours, sedation can limit the dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia (bed patients)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8211;200&#8239;mg daily in 3 divided doses, increased if necessary to 1&#8239;g daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8211;50&#8239;mg daily in divided doses, dose can be increased as necessary.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47491\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/levomepromazine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47525\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/levomepromazine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes</ph>; <ph outputclass=\"caution\">patients receiving large initial doses should remain supine</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p outputclass=\"title\">Elderly</p>\n<p>Risk of postural hypotension; not recommended for ambulant patients over 50 years unless risk of hypotensive reaction assessed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47366\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/levomepromazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Raised erythrocyte sedimentation rate</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47420\" outputclass=\"pregnancy\" parent=\"/drugs/levomepromazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47544\" outputclass=\"breastFeeding\" parent=\"/drugs/levomepromazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47458\" outputclass=\"hepaticImpairment\" parent=\"/drugs/levomepromazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47386\" outputclass=\"renalImpairment\" parent=\"/drugs/levomepromazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47564\" outputclass=\"directionsForAdministration\" rev=\"1.17\" parent=\"/drugs/levomepromazine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">subcutaneous</ph> use in children</p>\n<p>For administration by <i>subcutaneous infusion</i> dilute with a suitable volume of Sodium Chloride 0.9%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2234-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/levomepromazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74901\" title=\"Tablet\" namespace=\"/drugs/levomepromazine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74895\" title=\"Solution for injection\" namespace=\"/drugs/levomepromazine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"7\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"1\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_375\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/levomepromazine\" title=\"Levomepromazine\" count=\"1\" rel=\"link\">Levomepromazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74901\" namespace=\"/drugs/levomepromazine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74895\" namespace=\"/drugs/levomepromazine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2234",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/levomepromazine",
    "basename": "levomepromazine",
    "title": "LEVOMEPROMAZINE",
    "interactants": [
        {
            "id": "bnf_int_375",
            "label": "Levomepromazine"
        }
    ],
    "vtmid": "89029005",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Methotrimeprazine"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Pain in palliative care (reserved for distressed patients with severe pain unresponsive to other measures)",
                        "html": "Pain in palliative care (reserved for distressed patients with severe pain unresponsive to other measures)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "continuous subcutaneous infusion or intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By continuous subcutaneous infusion or by intramuscular injection or by intravenous injection",
                    "html": "By continuous subcutaneous infusion or by intramuscular injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Seek specialist advice.",
                        "html": "<p>Seek specialist advice.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Restlessness and confusion in palliative care",
                        "html": "Restlessness and confusion in palliative care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion"
                    ],
                    "textContent": "By subcutaneous infusion",
                    "html": "By subcutaneous infusion"
                },
                "child": [
                    {
                        "textContent": "0.35&#8211;3 mg/kg, to be administered over 24 hours.",
                        "html": "<p>0.35&#8211;3&#8239;mg/kg, to be administered over 24 hours.</p>",
                        "ageGroup": "1&#8211;11 years"
                    },
                    {
                        "textContent": "12.5&#8211;200 mg, to be administered over 24 hours.",
                        "html": "<p>12.5&#8211;200&#8239;mg, to be administered over 24 hours.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "6 mg every 2 hours as required.",
                        "html": "<p>6&#8239;mg every 2&#8239;hours as required.</p>"
                    },
                    {
                        "textContent": "6.25 mg every 2 hours as required.",
                        "html": "<p>6.25&#8239;mg every 2&#8239;hours as required.</p>"
                    },
                    {
                        "textContent": "Initially 12.5&#8211;50 mg/24 hours, titrated according to response (doses greater than 100 mg/24 hours should be given under specialist supervision).",
                        "html": "<p>Initially 12.5&#8211;50&#8239;mg/24 hours, titrated according to response (doses greater than 100&#8239;mg/24 hours should be given under specialist supervision).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting in palliative care",
                        "html": "Nausea and vomiting in palliative care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion"
                    ],
                    "textContent": "By subcutaneous infusion",
                    "html": "By subcutaneous infusion"
                },
                "child": [
                    {
                        "textContent": "100&#8211;400 micrograms/kg, to be administered over 24 hours.",
                        "html": "<p>100&#8211;400&#8239;micrograms/kg, to be administered over 24 hours.</p>",
                        "ageGroup": "1 month&#8211;11 years"
                    },
                    {
                        "textContent": "5&#8211;25 mg, to be administered over 24 hours.",
                        "html": "<p>5&#8211;25&#8239;mg, to be administered over 24 hours.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "6 mg once daily, dose to be taken at bedtime, increased if necessary to 12.5&#8211;25 mg twice daily.",
                        "html": "<p>6&#8239;mg once daily, dose to be taken at bedtime, increased if necessary to 12.5&#8211;25&#8239;mg twice daily.</p>"
                    },
                    {
                        "textContent": "6.25 mg once daily, dose to be given at bedtime, increased if necessary to 12.5&#8211;25 mg twice daily.",
                        "html": "<p>6.25&#8239;mg once daily, dose to be given at bedtime, increased if necessary to 12.5&#8211;25&#8239;mg twice daily.</p>"
                    },
                    {
                        "textContent": "5&#8211;25 mg/24 hours, sedation can limit the dose.",
                        "html": "<p>5&#8211;25&#8239;mg/24 hours, sedation can limit the dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia (bed patients)",
                        "html": "Schizophrenia (bed patients)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 100&#8211;200 mg daily in 3 divided doses, increased if necessary to 1 g daily.",
                        "html": "<p>Initially 100&#8211;200&#8239;mg daily in 3 divided doses, increased if necessary to 1&#8239;g daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia",
                        "html": "Schizophrenia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 25&#8211;50 mg daily in divided doses, dose can be increased as necessary.",
                        "html": "<p>Initially 25&#8211;50&#8239;mg daily in divided doses, dose can be increased as necessary.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes",
                "html": "Diabetes"
            },
            {
                "type": "cautions",
                "textContent": "patients receiving large initial doses should remain supine",
                "html": "patients receiving large initial doses should remain supine"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "title": "Elderly",
                "textContent": "Risk of postural hypotension; not recommended for ambulant patients over 50 years unless risk of hypotensive reaction assessed.",
                "html": "<p>Risk of postural hypotension; not recommended for ambulant patients over 50 years unless risk of hypotensive reaction assessed.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Raised erythrocyte sedimentation rate",
                        "html": "Raised erythrocyte sedimentation rate",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With subcutaneous use in children",
                    "html": "With <ph outputclass=\"route\">subcutaneous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "subcutaneous"
                    ]
                },
                "textContent": "For administration by subcutaneous infusion dilute with a suitable volume of Sodium Chloride 0.9%.",
                "html": "<p>For administration by <i>subcutaneous infusion</i> dilute with a suitable volume of Sodium Chloride 0.9%.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74901",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74895",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_375",
                "label": "Levomepromazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74901",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74895",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}